Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 1022-1029

  Oranje, Bob ^a,b   Glenthøj, Birte Y ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chronic schizophrenia; Clonidine; Noradrenaline; P50 suppression

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLONIDINE; NEUROLEPTIC AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MALE; MENTAL PATIENT; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SENSORY DYSFUNCTION; SENSORY EVALUATION; SENSORY GATING; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOLUNTEER; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; EVOKED RESPONSE; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; CLONIDINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SENSORY GATING; TREATMENT OUTCOME;

EID: 84900372579     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt144     Document Type: Article

References (36)

1. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001;156: 234-258.
2. Perry W, Geyer MA, Braff DL. Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry. 1999;56: 277-281.
3. Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull. 2006;32: 692-700.
4. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64: 1115-1122.
5. Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthoj BY. Sensory gating and its neural generators in antipsychotic-naïve, first-episode schizophrenia before and after 6 months of quetiapine treatment. Schizophr Bull. 2012;39: 472-480.
6. Powchik P, Davidson M, Haroutunian V, et al. Postmortem studies in schizophrenia. Schizophr Bull. 1998;24: 325-341.
7. Farley IJ, Price KS, McCullough E, Deck JH, Hordynski W, Hornykiewicz O. Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. Science. 1978;200: 456-458.
8. Yamamoto K, Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28: 913-922.
9. Clark CR, Geffen GM, Geffen LB. Catecholamines and attention. II: pharmacological studies in normal humans. Neurosci Biobehav Rev. 1987;11: 353-364.
10. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007;113: 523-536.
11. Bak N, Glenthoj BY, Rostrup E, Larsson HB, Oranje B. Source localization of sensory gating: a combined EEG and fMRI study in healthy volunteers. Neuroimage. 2011;54: 2711-2718.
12. Hammer TB, Oranje B, Bro H, Glenthoj BY. Stability of prepulse inhibition and habituation of the startle reflex in schizophrenia: a 6-year follow-up study of initially antipsychotic- naïve, first-episode schizophrenia patients. Int J Neuropsychopharmacol. 2011;4: 1-13.
13. Kumari V, Fannon D, Geyer MA, et al. Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex. 2008;44: 1206-1214.
14. Litman RE, Pickar D. Noradrenergic systems: a target for augmenting pharmacotherapy. In: Breier A, ed. The New Pharmacotherapy of Schizophrenia (Clinical Practice Series). Washington, DC: American Psychiatric Press; 1996: 133-152.
15. Friedman JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry. 1999;46: 1243-1252.
16. Arnsten AFT. Norepinephrine and cognitive disorders. In: Ordway GA, Schwartz MA, Frazer A, eds. Brain Norepinephrine, Neurobiology and Therapeutics. Cambridge, UK: Cambridge University Press; 2007: 408-435.
17. Fields RB, Van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings. Schizophr Res. 1988;1: 417-423.
18. Freedman R, Kirch D, Bell J, et al. Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr Scand. 1982;65: 35-45.
19. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27: 1145-1158.
20. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 2004;70: 315-329.
21. Aggernaes B, Glenthoj BY, Ebdrup BH, Rasmussen H, Lublin H, Oranje B. Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine. Int J Neuropsychopharmacol. 2010;13: 1383-1395.
22. McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother. 2009;10: 3061-3075.
23. Oranje B, Glenthøj BY. Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. Schizophr Bull. 2013;39: 684-691.
24. Adler LE, Hoffer L, Nagamoto HT, Waldo MC, Kisley MA, Giffith JM. Yohimbine impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology. 1994;10: 249-257.
25. Stevens KE, Meltzer J, Rose GM. Disruption of sensory gating by the alpha 2 selective noradrenergic antagonist yohimbine. Biol Psychiatry. 1993;33: 130-132.
26. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990;47: 589-593.
27. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276.
28. Berg P, Scherg M. A multiple source approach to the correction of eye artifacts. Electroencephalogr Clin Neurophysiol. 1994;90: 229-241.
29. Simpson KL, Lin RCS. Neuroanatomical and chemical organization of the locus coeruleus. In: Ordway GA, Schwartz MA, Frazer A, eds. Brain Norepinephrine, Neurobiology and Therapeutics. Cambridge, UK: Cambridge University Press; 2007: 9-52.
30. Reichenberg A, Harvey PD. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychol Bull. 2007;133: 833-858.
31. Weiland BJ, Boutros NN, Moran JM, Tepley N, Bowyer SM. Evidence for a frontal cortex role in both auditory and somatosensory habituation: a MEG study. Neuroimage. 2008;42: 827-835.
32. Blake TJ, Tillery CE, Reynolds GP. Antipsychotic drug affinities at alpha 2-adrenoceptor subtypes in post-mortem human brain. J Psychopharmacol. 1998;12: 151-154.
33. Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology. 2008;33: 497-512.
34. Quednow BB, Schmechtig A, Ettinger U, et al. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin- 1 Arg38Gln genotype: a replication study. Biol Psychiatry. 2009;66: 614-620.
35. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 1982;17: 639-654.
36. Kumari V, Peters ER, Fannon D, et al. Uncontrollable voices and their relationship to gating deficits in schizophrenia. Schizophr Res. 2008;101: 185-194.